...A. I am pleased to report that a quorum is present, with over 87% of the company's common and preferred stock entitled to vote at this meeting represented virtually on this web portal or by proxy. B. Total revenues were $48.3 billion, a 7% increase from the prior year. C. Our growth portfolio delivered double-digit growth with revenues of $22.6 billion, a 17% year-over-year increase. D. Our growth portfolio made up close to half of our total revenues, a strong indicator of how these products are propelling our ability to navigate the opportunities and challenges ahead. E. Our 2024 performance was achieved through our work to drive top-line growth, enhanced productivity and efficiency, and optimized operations across the organization. F. Last year, Bristol-Myers Squibb significantly advanced our pipeline with 23 regulatory approvals and indication expansions in the US and other markets. G. First, the landmark approval of COBENFY marked an important milestone. H. We enhanced our leadership...
